Centre Hospitalier Universitaire Vaudois Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4

Organization Overview

First Clinical Trial
2005
NCT00324623
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Andrej Trampuz | Brigitte Schürch | Chantal Csajka | Département des neurosciences cliniques Centre Hospitalier Universitaire Vaudois (CHUV); Lausanne | Dr Anna Dorothea Wagner | Dr. Romain Lazor | Prof. Serge Leyvraz

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Infections (Phase 2)

Malaria (Phase 4)

Melanoma (Phase 1)

Obstetric Labor, Premature (Phase 4)

Premature Birth (Phase 4)

Staphylococcal Infections (Phase 2)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 13